GlassScriptPhysician profile
Diane L Rowell
NPI 1356344964
$5,889.06
in general payments reported to CMS, 2019-2025
24 companies · $17.35 in 2025
The $17.35 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,364 · 2020: $1,104 · 2021: $1,469 · 2022: $1,287 · 2023: $564 · 2024: $84.25 · 2025: $17.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $570 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.30 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,235.40 | 2019-2024 | Breztri, Farxiga, Saphnelo |
| Janssen Pharmaceuticals, INC | $1,027.14 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $679.61 | 2019-2023 | |
| Abbvie INC. | $464.31 | 2021-2025 | Qulipta |
| Astellas Pharma US INC | $341.24 | 2019-2023 | Veozah, Myrbetriq |
| Pfizer INC. | $151.16 | 2019-2022 | |
| Allergan, INC. | $144.06 | 2019 | |
| Lilly USA, LLC | $109.80 | 2020-2024 | Zepbound, Jardiance |
| Boston Scientific Corporation | $107.34 | 2019 | |
| Sanofi-Aventis U.S. LLC | $106.64 | 2019-2022 | |
| Amgen INC. | $72.10 | 2019 | |
| Amarin Pharma, INC. | $69.95 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $66.43 | 2022 | |
| Mylan Specialty L.P. | $65.11 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $47.26 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.22 | 2019 | |
| Glaxosmithkline, LLC. | $32.63 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $26.71 | 2020-2022 | |
| Exact Sciences Corporation | $24.45 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $17.96 | 2021 | |
| Genentech USA, INC. | $16.75 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.11 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.94 | 2019 | |
| Neurelis, INC. | $14.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Rowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.